NEWARK, Del, April 10, 2023 (GLOBE NEWSWIRE) -- According to FMI estimations, the Autoimmune Disease Testing Market could increase from US$ 6.07 billion in 2023 to US$ 15.75 billion by 2033. The demand for autoimmune disease testing is likely to register a 10% CAGR during the forecast period.
The rising incidence of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, is fueling market expansion. This has increased the need for precise and trustworthy testing techniques to identify these problems at an early stage.
The market is also expanding given the improvements in diagnostic technology, including the creation of novel biomarkers and cutting-edge testing techniques. Healthcare professionals and patients are increasingly adopting these technologies since they offer fast, precise, and affordable testing solutions.
The demand for autoimmune disease testing is being driven by rising public awareness of autoimmune disorders as well as initiatives by healthcare organizations to inform patients and encourage early diagnosis. People are looking for rapid testing for early identification and management as they become aware of the signs and hazards of autoimmune illnesses.
Request a Sample Report with Table of Content @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16969
The market is largely driven by rising healthcare expenditures, particularly in developing nations. There is a rising need for autoimmune disease testing as governments and healthcare organizations engage in enhancing healthcare infrastructure and access to diagnostic services.
The adoption of point-of-care testing for autoimmune diseases is on the rise, driving the market growth. Point-of-care testing makes it possible to do quick and convenient tests at the patient's bedside or in other distant places. This eliminates the need for laboratory-based testing and yields speedier results.
The expansion of healthcare facilities in developing countries, coupled with increased access to healthcare services, is creating opportunities for the autoimmune disease testing market. As healthcare facilities expand and reach many patients, there is a high demand for autoimmune disease testing to diagnose and manage these conditions.
Key Takeaways
- The autoimmune disease testing market in the United States is growing significantly, driven by the increasing prevalence of autoimmune diseases and advancements in diagnostic technologies.
- The autoimmune disease testing market in the United Kingdom is experiencing growth due to the rising prevalence of autoimmune diseases which is driving demand for accurate and efficient testing methods.
- The autoimmune disease testing market in China is notably expanding, propelled by the growing population, changing lifestyles, and increased awareness about autoimmune diseases.
- The reagents and consumables segment holds a dominant position in the autoimmune disease testing market as it serves as a critical component in the diagnostic process.
- The C-Reactive Protein (CRP) segment continues to dominate the autoimmune disease testing market, driven by its high sensitivity and specificity in detecting inflammation and infection.
Competitive Landscape:
The development of novel and precise diagnostic tests for autoimmune disorders is a top priority for manufacturers. To increase the sensitivity and specificity of tests, they are investing in cutting-edge technologies including point-of-care testing, molecular diagnostics, and immunoassays.
By releasing new autoimmune disease testing kits and platforms, manufacturers are also concentrating on diversifying their product lines. To take advantage of resources and skills that complement one another, they are also forging strategic partnerships with other businesses, research institutes, and laboratories. These alliances are designed to hasten the creation and distribution of innovative tests for autoimmune diseases.
Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-16969
Key Players:
F. Hoffmann-La Roche Ltd, ZEUS Scientific, Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Abbott, SQI Diagnostics Inc., Werfen, Trinity Biotech, KSL Beutner Laboratories (Beutner), Bio-Rad Laboratories, Inc. and others.
Recent Developments:
- The United States Food and Drug Administration granted Werfen 501(K) clearance in June 2021 for the Aptiva Celiac Disease IgA and IgG tests. Also, the Aptiva CTD (connective tissue disease) essential panel was given the CE mark by the firm.
- The Vectra test report had a significant upgrade in February 2021 by Myriad Genetics Inc. A unique assessment of a patient's one-year risk of fast radiographic development is provided in the new test result (RP). According to the patient's age, gender, and adiposity, the RP result is unique to each report.
Autoimmune Disease Testing Market Segmentation:
Autoimmune disease testing industry by product type:
- Instruments
- Reagents & consumables
Autoimmune disease testing industry by disease type:
- Rheumatoid arthritis (ra)
- Systemic lupus erythematosus (sle)
- Scleroderma
- Vasculitis
- Inflammatory bowel disease (ibd)
- Others
Autoimmune disease testing industry by test type:
- Antinuclear autoantibody (ana)
- Rheumatoid factor (rf)
- C-reactive protein (crp)
- Anti-thyroglobulin antibody (ata)
- Others
Autoimmune disease testing industry by end user:
- Hospital & clinics
- Diagnostic centers
- Others
Click here today to buy your full report @ https://www.futuremarketinsights.com/checkout/16969
Table of Content
1. Executive Summary | Autoimmune Disease Testing Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
Complete TOC with Report Preview @ https://www.futuremarketinsights.com/reports/autoimmune-disease-testing-market
Have a Look at Related Research Reports in the Healthcare Domain:
Hyperinsulinemia Hypoglycaemia Treatment Market Size - According to FMI, the market for hyperinsulinemia hypoglycemia treatment is foreseen to rise to US$ 100 million in FY 2023, representing a Y-o-Y increase of over 4%. Across the forecast period ranging from 2023 to 2033
Uncomplicated Urinary Tract Infection Treatment Market Share - The global uncomplicated urinary tract infection treatment market garnered a market value of US$ 5.96 Billion in 2022 and is expected to accumulate a market value of US$ 17 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033.
Stereotactic Surgery Devices Market Trends - The stereotactic surgery devices market is expected to increase at a 4.1% CAGR from 2023 to 2033, from US$ 26.34 billion in 2023 to US$ 39.36 billion in 2033.
Short-read Sequencing Market Demand - The short-read sequencing market size is projected to be valued at US$ 6,322.03 million in 2023 and is expected to rise to US$ 34,401.22 million by 2033. The sales of short-read sequencing are projected to expand at a significant CAGR of 18.46% during the forecast period.
Predictive Disease Analytics Market Forecast - According to the recent report by Future Market Insights (FMI), the predictive disease analytics market size is estimated to stand at US$ 18.64 billion by 2033. Over the forecast period, the market is assessed to trail at a CAGR of 22.5%. For the year 2023, the market is estimated to be worth US$ 2.45 billion.
About Future Market Insights, Inc.
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
